US Edition
Long-Lasting Insulin Takes Another Step Forward with Latest Clinical Trial Results
- Eli Lilly disclosed the outcomes of the Phase 3 QWINT-1, QWINT-3, and QWINT-4 studies evaluating once-weekly insulin efsitora alfa for treating patients with type 2 diabetes requiring insulin therapy at the ADA 85th Scientific Sessions held on June 22, 2025, in Chicago.
- These trials began in 2022 to evaluate efsitora's safety and efficacy, aiming to prove noninferiority in reducing HbA1c versus daily basal insulins, with no guarantee of future approval or consistent results.
- Efsitora achieved HbA1c reductions from 8.20% to 7.05% at week 52, comparable to insulin glargine, and showed lower rates of clinically significant hypoglycemia while enabling a simpler fixed-dose weekly regimen.
- Jeff Emmick said efsitora may eliminate over 300 injections annually, and Julio Rosenstock called the fixed-dose approach a potential paradigm shift, while 76% maintained fixed doses through the trial.
- Eli Lilly aims to seek regulatory approval for efsitora by the end of 2025, offering a once-weekly insulin option that could make diabetes management easier for many; however, its widespread use will likely depend on factors such as pricing, insurance coverage, and accessibility.
50 Articles
50 Articles
San Diego Union Tribune
Long-lasting insulin takes another step forward with latest clinical trial results
On Sunday in Chicago, Dr. Athena Philis-Tsimikas, vice president of San Diego’s Scripps Whittier Diabetes Institute, helped deliver positive news for the estimated 7 million Americans who take insulin every day to manage their type 2 diabetes. The endocrinologist and researcher was one of several investigators who presented Phase 3 clinical trial results at the 85th Scientific Sessions of the American Diabetes Association for a long-lasting type…
MedPage Today
Anti-Aging, Acupuncture and Health NewsOnce-Weekly Basal Insulin Non-Inferior to Several Daily Options in Type 2 Diabetes
(MedPage Today) -- CHICAGO -- A once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the phase III QWINT development program found. In QWINT-1, there was a similar HbA1c reduction with...
Rutland Herald
Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials
Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing
Once-weekly insulin could be ‘game changer’ for adults with type 2 diabetes
CHICAGO — A once-weekly basal insulin conferred similar HbA1c to once-daily insulins among adults with type 2 diabetes, both in previous basal insulin users and first-time insulin users, according to data from the QWINT trials. At the American Diabetes Association Scientific Sessions, researchers presented findings from the QWINT-1, QWINT-3 and QWINT-4 trials, which assessed once-weekly
Coverage Details
Bias Distribution
- 73% of the sources are Center
To view factuality data please Upgrade to Premium
